Clinical Trial 49937

Phoenix, AZ 85013


The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.

The goal of this Phase 0 study is to confirm that niraparib is capable of crossing the blood-brain barrier. Patients with positive results may advance to an expansion phase that combines therapeutic dosing of niraparib in combination with standard-of-care fractionated radiotherapy.

The expansion phase of this study will examine progression-free survival and monitor safety and tolerability of niraparib in combination with radiation.

  • PARP (poly ADP ribose polymerase) is a protein that plays an important role in cell survival response to DNA damage.
  • Niraparib (the treatment agent) is an oral, highly selective PARP inhibitor that blocks the tumor cell survival response.
  • Niraparib is approved by the FDA for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

  • You are 18 years or older
  • You have a suspected newly diagnosed glioblastoma
  • You plan on following the standard treatment regimen, including surgical resection and radiation

Qualified Participants May Receive:

As part of a clinical trial at the Ivy Brain Tumor Center, the study drugs will be provided free of charge, however, the patient and/or their health plan/insurance company will be responsible for some or all of the costs of treating the tumor in the study, including any standard medical care such as surgical resection.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.